Kelso Pharma announces that Allan Watson, the company’s Chief Financial Officer, has decided to retire from his role and is being succeeded by life sciences financial specialist, Alan King. More here: bit.ly/3UVyVjn 🌍🤝

“It is a privilege to have been given this opportunity to play my part in the next chapter of the Kelso growth story…” – Chief Financial Officer, Kelso Pharma. Read more here: bit.ly/3UVyVjn 🌍🤝

Kelso Pharma operates across 47 countries, with over 80 partners. Our team continues to work hard to grow the business and support as many patients as possible.

At Kelso Pharma, we are committed to our ESG mission. This means maintaining continuity of supply, ensuring affordability and patient access, and taking clear steps to reduce our carbon emissions across the supply chain.

We work with partners across Europe and beyond to bring effective, value-added medicines to new markets. Learn more on our website: bit.ly/3r9bP9G

By innovating on existing treatments, we aim to create medicines that easily fit into patients’ daily routines, helping to improve lives. Learn more on our website: bit.ly/3r9bP9G

ALTURiX has seven branded medicines in the UK market today. These are in the therapeutic areas of: 🔹 Central nervous system 🔹 Respiratory disease 🔹 Endocrinology Learn more about ALTURiX: alturix.com

Ethical practices come first at Kelso Pharma. Across the development of all our products, we take into account factors such as sustainability and affordability, as we look to improve healthcare systems for everyone.

Our team is working hard to provide greater availability for a number of high quality medicines that will enhance the lives of patients across Europe. Learn more on our website: bit.ly/3r9bP9G

With Stirling Anglian Pharmaceuticals and ALTURiX, we have been growing our UK portfolio. We are proud of the positive impact we continue to make - supplying complex, patient-centric medicines to the NHS and other international markets.

Continuity of supply, affordability and patient access for our medicines are vital for us and key to building meaningful partnerships. Learn more on our website: bit.ly/3r9bP9G

What drives us is the opportunity to create medicines that add real value to the healthcare system, whilst helping to improve the lives of patients across Europe. Learn more on our website: bit.ly/3r9bP9G

We are focused on company M&A, product acquisitions and in-licensing, as we grow our operations across Europe. This will strengthen our ability to develop and deliver affordable, innovative, value-added, specialty medicines which support healthcare systems around the world.

Say hello to Kelso Pharma Italy! 🤝 Kelso Pharma announces that Velit Biopharma will trade as ‘Kelso Pharma Italy’ from today (21 October 2025), as the business gears up for further growth across European markets. Read more here: bit.ly/4nY4gif🌍🔗

Building a European specialty pharma group Since 2021, Kelso Pharma has grown from launch to a cross-European specialty business through strategic acquisitions, strong partnerships, and a clear focus on value-added medicines.

Meeting the demand for complex, niche medicines. 🤝 We are focused on improving existing niche medicines and prioritising practical solutions that fit seamlessly into patients’ daily routines. Learn more on our website: bit.ly/3r9bP9G